SCHEMBL29378607

SCHEMBL29378607

COP(=O)(OC)SCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.69
MAPT P10636 2/20 0.69
PLIN1 O60240 1/20 0.69
HPGD P15428 1/20 0.69
ALOX15 P16050 1/20 0.69
PLIN5 Q00G26 1/20 0.69
ABHD5 Q8WTS1 1/20 0.69
MAPK1 P28482 1/20 0.45
NPC1 O15118 2/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5933920 1.00 ALDH1A1 (0.69) ALDH1A1MAPTPLIN1HPGDALOX15
SCHEMBL17602874 0.84 ALDH1A1 (0.57) ALDH1A1MAPTPLIN1HPGDALOX15
SCHEMBL11115778 0.83 ALDH1A1 (0.64) ALDH1A1MAPTPLIN1HPGDALOX15
Phosmet SCHEMBL3620 0.82 ALDH1A1 (1.00) ALDH1A1MAPTPLIN1HPGDALOX15
Phosmet SCHEMBL1663406 0.82 ALDH1A1 (1.00) ALDH1A1MAPTPLIN1HPGDALOX15
Phosmet SCHEMBL29350557 0.82 ALDH1A1 (1.00) ALDH1A1MAPTPLIN1HPGDALOX15
SCHEMBL13596981 0.76 ALDH1A1 (0.81) ALDH1A1MAPTPLIN1HPGDALOX15
SCHEMBL571793 0.75 PLIN1 (0.55) ALDH1A1MAPTPLIN1HPGDALOX15
Phosmet SCHEMBL7246728 0.75 ALDH1A1 (0.84) ALDH1A1MAPTPLIN1HPGDALOX15
SCHEMBL4124410 0.75 ALDH1A1 (0.54) ALDH1A1MAPTPLIN1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032519-A1 HIGH POTENCY EMULSIONS VERTOSA INC. 2025-01-30 US claimed
CN-118871116-A Compounds for the treatment of cancer 卡希夫生物科学有限公司 2024-10-29 CN claimed
US-20240342066-A1 HIGH POTENCY EMULSIONS VERTOSA INC. 2024-10-17 US claimed
CN-117177965-A Five-membered and six-membered compound, preparation method, pharmaceutical composition and application 杭州多域生物技术有限公司 2023-12-05 CN claimed
EP-3805243-B1 ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF HEART FAILURE WINDTREE THERAPEUTICS INC (US) 2023-11-15 EP claimed
US-12557062-B2 Method and apparatus for processing data flow of positioning base station, device and computer-readable medium GREE ELECTRIC APPLIANCES (WUHAN) CO., LTD (CN) 2026-02-17 US disclosed
EP-4652275-A1 DELIVERY OF OLIGONUCLEOTIDES ProQR Therapeutics II B.V. (NL) 2025-11-26 EP disclosed
US-20250340934-A1 SELECTIVE BLOCKING TO DETECT AND AMPLIFY LOW ABUNDANT TEMPLATE GT MOLECULAR, INC. (US) 2025-11-06 US disclosed
WO-2025226735-A1 CHEMICAL IMPAIRMENT DETECTION AND PROPULSION CONTROL (CIDPC) SYSTEM #1 A LIFESAFER, INC. (US) 2025-10-30 WO disclosed
EP-4641119-A2 SYSTEMS, METHODS, AND APPLIANCES THAT ENABLE REGIONAL CONTROL OF REFRIGERATION APPLIANCES True Manufacturing Co., Inc. (US) 2025-10-29 EP disclosed
EP-4591460-A1 APPARATUS AND METHODS FOR PHASE DETERMINATION IN MULTI-BEAM COMMUNICATION SYSTEMS QUALCOMM INCORPORATED (US) 2025-07-30 EP disclosed
WO-2025122524-A1 CONTROL SYSTEM AND METHOD ADJ PRODUCTS, LLC (US) 2025-06-12 WO disclosed
CN-114630826-A Fluorinated quinoline, quinoxaline and benzo [ b ] [1,4] oxazine derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases 詹森生物科技公司 2022-06-14 CN disclosed
EP-4002865-A1 SERVICE CONFIGURATION METHOD AND APPARATUS ZTE Corporation (CN) 2022-05-25 EP disclosed
CN-114423759-A Condensed heteroaryl derivative, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-04-29 CN disclosed
CN-108885660-B Techniques for metadata processing 查尔斯斯塔克德雷珀实验室有限公司 2022-04-05 CN disclosed
CN-114222739-A Sulfonylurea derivatives and use thereof 诺瑟拉有限公司 2022-03-22 CN disclosed
EP-3957034-A1 SUBSCRIBER STATION FOR A SERIAL BUS SYSTEM, AND METHOD FOR COMMUNICATING IN A SERIAL BUS SYSTEM Robert Bosch GmbH (DE) 2022-02-23 EP disclosed
CN-113057609-B Vital sign monitoring method and system 吉林大学 2022-02-18 CN disclosed
CN-114026060-A Acrylate derivative, use thereof, and intermediate for production thereof 住友化学株式会社 2022-02-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12557062-B2 Method and apparatus for processing data flow of positioning base station, device and computer-readable medium RAD1, SET, BUB1 ALDH1A1 4846/4885MAPT 2444/4885PLIN1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.